The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

42 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986).EBI
Charles River Discovery Research Services
Structure-based design and optimization of potent inhibitors of the adenoviral protease.EBI
Novartis Institute For Biomedical Research
Cathepsin C inhibitors: property optimization and identification of a clinical candidate.EBI
Astrazeneca
Discovery of novel cyanamide-based inhibitors of cathepsin C.EBI
TBA
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University of Florida
Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing.EBI
Merck Research Laboratories
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.EBI
Merck Frosst Centre For Therapeutic Research
Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C.EBI
Merck Frosst Canada
Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB.EBI
National Human Genome Research Institute
Substrate optimization for monitoring cathepsin C activity in live cells.EBI
Genomics Institute of The Novartis Research Foundation
Bicyclic carbamates as inhibitors of papain-like cathepsin proteases.EBI
The Genomics Institute of The Novartis Research Foundation
Non-peptidyl non-covalent cathepsin C inhibitoEEr bearing a unique thiophene-substituted pyridine: Design, structure-activity relationship and anti-inflammatory activity in vivo.EBI
Anhui Medical University
Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors.EBI
Arpida
Discovery and EBI
Anhui Medical University
Development of potent and selective Cathepsin C inhibitors free of aortic binding liability by application of a conformational restriction strategy.EBI
Glenmark Research Centre
Optimization of the EBI
Novartis Pharma
Lung Protection by Cathepsin C Inhibition: A New Hope for COVID-19 and ARDS?EBI
Centre D'Etude Des Pathologies Respiratoires and Universit£
Identification and Optimization of Novel Cathepsin C Inhibitors Derived from EGFR Inhibitors.EBI
National Institute of Biological Sciences (Nibs)
DPP1 Inhibitors: Exploring the Role of Water in the S2 Pocket of DPP1 with Substituted Pyrrolidines.EBI
Astrazeneca
Carboxyl-modified amino acids and peptides as protease inhibitors.EBI
TBA